Amgen And Synaffix Alliance Could Be Biggest Preclinical ADC Licensing Deal Yet
Adds To ADC Dealmaking Frenzy
Amgen has signed two big early-stage deals in a matter of days, signalling that antibody-drug conjugates are a priority target in oncology for the firm.
